Correction: Continuous Subcutaneous    Foslevodopa/Foscarbidopa   in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Aldred, J; Freire-Alvarez, E; Amelin, AV; Antonini, A; Bergmans, B; Bergquist, F; Bouchard, M; Budur, K; Carroll, C; Chaudhuri, KR; Criswell, SR; Danielsen, EH; Gandor, F; Jia, J; Kimber, TE; Mochizuki, H; Robieson, WZ; Spiegel, AM; Standaert, DG; Talapala, S; Facheris, MF; Fung, VSC

View/Open

Correction Continuous Subcutaneous FoslevodopaFoscarbidopa in Parkinsons Disease Safety and Efficacy Results From a 12-Month.pdf (167.9Kb)

Date

2023-10-10

Author

Aldred, J

Freire-Alvarez, E

Amelin, AV

Antonini, A

Bergmans, B

Bergquist, F

Bouchard, M

Budur, K

Carroll, C

Chaudhuri, KR

Criswell, SR

Danielsen, EH

Gandor, F

Jia, J

Kimber, TE

Mochizuki, H

Robieson, WZ

Spiegel, AM

Standaert, DG

Talapala, S

Facheris, MF

Fung, VSC

Subject

32 Biomedical and Clinical Sciences

3202 Clinical Sciences

Metadata

Show full item record

Abstract

Correction: Neurol Ther https://doi.org/10.1007/s40120-023-00533-1

Publisher

Springer Science and Business Media LLC

Place of Publication

New Zealand

Journal

Neurology and Therapy

Volume

Issue

Pagination

1959-1960

Author URL

https://www.ncbi.nlm.nih.gov/pubmed/37817017

Publisher URL

http://dx.doi.org/10.1007/s40120-023-00554-w

Recommended, similar items

The following license files are associated with this item:

Original License